drugset / Trial / NCT02429700
TC or BEP in Treating Patients With Ovarian Malignant Sex Cord-Stromal Tumors
Phase 3
Recruiting
132 enrolled
Beihua Kong
Huazhong University of Science and Technology · collabSun Yat-sen University · collabZhejiang University · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
Investigators will conduct the trial to determine whether paclitaxel and cisplatin (PT) has the same curative effects and less adverse effects than bleomycin, etoposide and cisplatin(BEP) among newly diagnosed ovarian malignant sex cord-stromal tumor patients after surgery.
Timeline
- Start
- 2015-04
- Primary completion
- 2025-05
- Completion
- 2030-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Bleomycin | Unknown | 30000 iu | Intramuscular |
| Subject | Carboplatin | Small molecule | — | Intravenous |
| Comparator | Cisplatin | Other / unclassified | 20 mg/m2 | Intravenous |
| Comparator | Etoposide | Small molecule | 100 mg/m2 | Intravenous |
| Subject | Paclitaxel | Small molecule | 175 mg/m2 | Intravenous |